home / stock / eftr / eftr news

EFTR News and Press, eFFECTOR Therapeutics Inc. From 10/11/21

Stock Information
Company Name: eFFECTOR Therapeutics Inc.
Stock Symbol: EFTR
Market: OTC
Website: effector.com
Menu
EFTR EFTR Quote EFTR Short EFTR News EFTR Articles EFTR Message Board
Get EFTR Alerts

News, Short Squeeze, Breakout and More Instantly...
EFTR - APRN, CEI and GOTU among mid-day movers

Gainers: Protagonist (NASDAQ:PTGX) +86%. Adamas (NASDAQ:ADMS) +75%. Flexion (NASDAQ:FLXN) +63%. Progenity (NASDAQ:PROG) +35%. Gaotu Techedu (NYSE:GOTU) +23%. U.S. Well Services (NASDAQ:USWS) +22%. Blue Apron (NYSE:APRN) +19%. EZFill (NASDAQ:EZFL) +18%. Ocular (NASDAQ:OCUL) +17%. Willamette Va...
EFTR - Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by increasing production of proteins involved in interferon- α and interferon- �...

EFTR - Voyager Therapeutics, Molecular Partners leads healthcare gainers; Ginkgo Bioworks, OpGen among major losers

Gainers: Voyager Therapeutics (NASDAQ:VYGR) +57%, Acer Therapeutics (NASDAQ:ACER) +9%, Molecular Partners (NASDAQ:MOLN) +10%, Rafael (NYSE:RFL) +6%, Arcturus Therapeutics (NASDAQ:ARCT) +7%. Losers: Ginkgo Bioworks (NYSE:DNA) -21%, OpGen (...

EFTR - Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that eFFECTOR-supported research from Baylor College of Medicine entitled, ...
EFTR - Hold Off on eFFECTOR Therapeutics if You Can't Stomach the Risk

InvestorPlace - Stock Market News, Stock Advice & Trading Tips As you may be aware, some business combinations with special purpose acquisition companies (SPACs) have not gone well. But one exception — at least so far — is eFFECTOR Therapeutics (NASDAQ: EFTR ) and...

EFTR - ReWalk Robotics, NanoViricides leads healthcare gainers; Edesa Biotech, Verrica Pharmaceuticals among major losers

Gainers: ReWalk Robotics (NASDAQ:RWLK) +36%, NanoViricides (NYSE:NNVC) +36%, Inotiv (NASDAQ:NOTV) +27%, Solid Biosciences (NASDAQ:SLDB) +22%, eFFECTOR Therapeutics (NASDAQ:EFTR) +16%. Losers: Edesa Biotech (NASDAQ:EDSA) -25%, Verrica Pharmaceuticals (NASDAQ:...

EFTR - eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Special purpose acquisition companies (SPACs) can be exciting to invest in, though there are always risks involved. This should definitely be kept in mind with eFFECTOR Therapeutics  (NASDAQ: EFTR ), as EFTR stock...
EFTR - eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor V...

EFTR - CLMT, ATER and MTNB among mid-day movers

Gainers: Communications Systems (NASDAQ:JCS) +33%. BELLUS Health (NASDAQ:BLU) +20%. Matinas BioPharma (NYSE:MTNB) +19%. Onion Global (NYSE:OG) +18%. FuelCell Energy (NASDAQ:FCEL) +17%. Silverback Therapeutics (NASDAQ:SBTX) +16%. DatChat (NASDAQ:DATS) +15%. Calumet (NASDAQ:CLMT) +15%. Ada...

EFTR - BELLUS Health, aTyr Pharma leads healthcare gainers; Virpax Pharmaceuticals, RedHill Biopharma among major losers

Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Bi...
Previous 10 Next 10